At Angiotech, we are redefining success by striving to create novel medical solutions that elevate the standard of care and improve people's lives.
Angiotech is Redefining Success
- Angiotech is a global specialty pharmaceutical and medical device company that discovers, develops, and markets innovative technologies and medical products primarily for local diseases or for complications associated with medical device implants, surgical interventions and acute injury. We are listed on both the TSX and NASDAQ stock exchanges (NASDAQ: ANPI, TSX: ANP). Read More...
If you are a Healthcare Professional and would like to learn more about Angiotech's products, please visit AngioEduPRO.com; Angiotech's Educational Resource for Healthcare Professionals.
Press Releases
- June 8th - Angiotech Pharmaceuticals Announces FDA 510(K) Clearance of the Option™ Inferior Vena Cava Filter Read More...
- June 3rd - Angiotech Enters License, Distribution and Supply Agreements for Fibrin and Thrombin Technologies with Haemacure Corporation Read More...
- All Press Releases
Highlights
- Angiotech's Annual General Meeting Presentation View Now...
- June 4th set as date of Annual General Meeting of Shareholders Read More...
- Angiotech's Quarterly Results Read More...
